Company Focus
Overview
Price Chart
Key Metrics
Valuation
Financials
Earnings
Dividends
Analyst Ratings
Insider Trades
Events Timeline
News + Sentiment
Peer Comparison
Immunovant
IMVT Mid CapHealthcare · Biotechnology
Updated: May 22, 2026, 22:06 UTC
Key Metrics
Valuation Analysis
About the Company
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant Stock at a Glance
Immunovant (IMVT) is currently trading at $34.15 with a market capitalization of $7B. The 52-week range spans from $13.79 to $36.28; the current price is 5.9% below the yearly high.
💰 Dividend
Immunovant currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
17 analysts rate Immunovant (IMVT) on consensus: Buy. The average price target is $41.29, implying +20.92% from the current price. Analyst price targets range from $22.00 to $66.00.
Investment Thesis: Strengths & Weaknesses
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 0.01)
- –High short interest (20.89%)
- –Negative free cash flow
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (20.89%).
Trading Data
Related Stocks in the Same Sector
Immunovant 2026: IMVT-1402 Next-Gen Anti-FcRn, Graves' Disease Phase 3 and the Roivant Strategic Overhang
The Real Story
Immunovant is a clinical-stage immunology platform company developing next-generation anti-FcRn (neonatal Fc receptor) monoclonal antibodies for a broad portfolio of IgG-driven autoimmune diseases. The company is 57% owned by Roivant Sciences (NYSE: ROIV), and was specifically created and capitalized to compete in the anti-FcRn category dominated by argenx Vyvgart (efgartigimod) which generated USD 2.0 bn revenue in 2024-2025 across generalized myasthenia gravis, ITP and CIDP. FY2025 revenue zero (pre-commercial), reported net loss USD 2.67 per share, free cash flow -USD 260 M. The current ratio of 15.74 reflects approximately USD 750 M cash and equivalents at end-2025 — runway through 2027 without further capital.
The 2026 strategic story has two threads. First, IMVT-1402: a next-generation anti-FcRn engineered to deliver deep IgG suppression (similar to first-generation efgartigimod) with substantially less albumin reduction — a key differentiating biomarker. Phase 1 healthy-volunteer data in 2024 showed 80%+ IgG reduction with under 5% albumin reduction (vs efgartigimod 25-30% albumin reduction at therapeutic doses). The pivotal MOMENTUM Phase 3 in Graves' disease (a 1.5 M US-patient population with no FDA-approved biologic) reads out primary endpoint in H2/2026 with interim safety review mid-2026. Second, the multi-indication strategy: IMVT-1402 has parallel Phase 2-3 programs in rheumatoid arthritis, myasthenia gravis, CIDP, cutaneous lupus erythematosus and Sjögren's disease. Batoclimab (first-generation Immunovant anti-FcRn) is in confirmatory Phase 3 trials in myasthenia gravis and CIDP with results 2026.
The 2026 question is whether the MOMENTUM Phase 3 Graves' disease readout confirms IMVT-1402's clinical and biomarker differentiation, whether the breadth-of-indication strategy converts into multiple commercial opportunities, and whether Roivant Sciences moves to monetise its 57% stake through a strategic transaction or sell-down.
What Smart Money Thinks
Top holders Q1/2026: Roivant Sciences (controlling parent since 2018) approximately 57.0%, Vanguard 3.4%, BlackRock 2.6%, Baker Bros Advisors 2.1%, RA Capital Management 1.8%, T. Rowe Price 1.6%, Fidelity 1.5%. Free-float effectively 43% with Roivant as the strategic-overhang factor.
Most interesting move: Baker Bros increased its position 22% in Q4/2025 — sustained specialist accumulation despite Roivant overhang. T. Rowe Price opened a fresh 1.6% position in Q1/2026 at USD 25-28 prices — first large-cap-growth-fund accumulation, signaling conviction in the multi-indication thesis. Notably, Roivant itself has not sold any IMVT shares since 2021 — a credible signal that Roivant management sees the 57% stake as a long-duration value-creation lever rather than a short-term monetization opportunity. RA Capital trimmed 12% in Q1/2026 — modest reduction, not a thesis change.
Insider activity: CEO Pete Salzmann (in role since 2018) made no open-market purchases in 2024-2025 — typical restraint. CFO Renee Barnett bought USD 250k in Q4/2025 at USD 22 — first major insider purchase since 2022. Roivant Chairman Vivek Ramaswamy (Roivant founder, no longer CEO) has not transacted in IMVT directly. Notably, board member Eric Venker (Roivant President) bought USD 300k in Q1/2026 — a credible signal from Roivant operating leadership that the Immunovant value-creation thesis is intact.
Short interest 20.9% (short ratio 11.5 days to cover) — elevated. The bear thesis is concentrated on (1) MOMENTUM Phase 3 Graves' clinical-readout binary risk, (2) argenx Vyvgart competitive entrenchment in established indications and possible Graves' label expansion, (3) the Roivant 57% overhang representing potential dilution event or strategic-acquirer impasse, and (4) cash-burn rate of USD 260+ M annually requiring 2027 capital raise.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Phase 1 healthy-volunteer data showed IMVT-1402 delivering 80%+ IgG reduction with under 5% albumin reduction — a clean differentiation from efgartigimod (25-30% albumin reduction at therapeutic doses). For chronic autoimmune use, lower albumin reduction means less peripheral edema, less risk of pleural/peritoneal effusion, and a better safety profile that supports prolonged-duration therapy. If MOMENTUM Phase 3 in Graves' disease confirms the safety differentiation alongside efficacy, IMVT-1402 becomes the preferred anti-FcRn for chronic indications. Peak-sales potential across all indications USD 5-10 bn globally if the differentiation thesis holds.
Graves' disease is the autoimmune hyperthyroidism affecting approximately 1.5 M US patients and 30 M globally. Current standard of care is antithyroid drugs (methimazole, propylthiouracil), radioactive iodine ablation, or thyroidectomy — all with significant patient-experience burden and many requiring lifelong hormone replacement. No FDA-approved biologic exists for Graves'. If IMVT-1402 demonstrates 50%+ ATD-free euthyroid remission at 24 weeks (the MOMENTUM primary endpoint), it becomes the first targeted biologic in a virgin market with USD 8-12 bn peak sales potential at conservative pricing. The MOMENTUM trial is the largest single-indication catalyst in autoimmune biotech 2026.
IMVT-1402 has parallel Phase 2-3 programs in six indications (Graves', myasthenia gravis, CIDP, RA, cutaneous lupus, Sjögren's) plus batoclimab confirmatory Phase 3 in MG and CIDP. The platform thesis is that anti-FcRn mechanism applies broadly to IgG-driven autoimmune diseases, and the multi-indication approach diversifies clinical-readout risk while building a category franchise. Even modest success across two-to-three indications justifies USD 3-5 bn peak revenue. The platform discovery program is also developing oral anti-FcRn small molecules and subcutaneous-formulation enhancements.
📉 The 3 Real Bear Points
The MOMENTUM Phase 3 primary endpoint reads out H2/2026 — a single positive/negative trial result. Bear case: the Phase 2 efficacy was modest (40-45% response rate, with placebo around 30%) and the Phase 3 design uses a more stringent primary endpoint with more challenging baseline-disease severity inclusion criteria. If MOMENTUM misses primary endpoint, IMVT-1402 Graves' commercial opportunity is delayed by 18-24 months pending Phase 4 or label-bridging studies, and the platform-validation thesis takes a significant hit. The market is pricing 65-70% probability of clean MOMENTUM win — leaving meaningful drawdown risk on negative readout.
argenx Vyvgart (efgartigimod) launched 2021 in generalized myasthenia gravis, expanded to ITP 2024 and CIDP 2024 — reaching USD 2.0 bn revenue 2025. Argenx has accumulated commercial infrastructure, payer relationships, and patient-access programs that take 2-3 years to build. argenx Phase 3 ADHERE-CIDP and ADAPT-NXT MG are ongoing with strong real-world evidence. Critically, argenx is in Phase 2 Graves' disease with data expected 2026-2027 — if argenx data comes earlier or matches IMVT-1402, the differentiation thesis weakens. Argenx is also testing subcutaneous and oral formulations as defensive moves.
Roivant Sciences (ROIV) owns 57% of IMVT. The strategic options for Roivant include: (a) sell the IMVT stake to a strategic acquirer (likely large pharma — Novartis, Pfizer, BMS); (b) distribute IMVT shares to ROIV shareholders; (c) hold long-term. Option (a) would trigger an IMVT change-of-control event at a likely 30-50% premium but caps independent upside. Option (b) is dilutive in the short-term as ROIV shareholders may sell distributed shares. The optionality is structurally negative for medium-term price stability — large traders avoid IMVT until Roivant signals its strategic intent.
Valuation in Context
P/E meaningless (no profits). P/S meaningless (no revenue). P/B 5.67x is the only standard metric — reflects pre-commercial biotech multiple. The right framework is risk-adjusted sum-of-parts NPV. Graves' disease NPV (assuming 65% MOMENTUM win + 20% peak penetration + USD 80k pricing) approximately USD 4.0 bn. Myasthenia gravis NPV (batoclimab + IMVT-1402) USD 1.0 bn. CIDP NPV USD 0.6 bn. RA, lupus, Sjögren's NPV USD 1.5 bn risk-adjusted. Total NPV USD 7.0-7.5 bn versus current enterprise value approximately USD 4.8 bn (USD 5.6 bn market cap minus USD 0.75 bn cash). Sell-side PT consensus USD 40.29 (range USD 22-66): Goldman Sachs most bullish at USD 66 (MOMENTUM wins + multi-indication platform + Roivant strategic transaction), HSBC most bearish at USD 22 (MOMENTUM misses + argenx Graves' competitive + Roivant overhang persists). 17 analysts cover, recommendation classified as buy/neutral split. Implied probability of MOMENTUM win in current price approximately 65%. Bull case USD 60 (+118%) on MOMENTUM win + Roivant strategic move + multi-indication validation. Bear case USD 12 (-56%) on MOMENTUM miss + argenx Graves' data + cash dilution required.
🗓️ Next 3 Catalyst Dates
- Mid 2026: MOMENTUM Phase 3 Graves' disease interim safety review
- H2 2026: Batoclimab confirmatory Phase 3 in myasthenia gravis and CIDP — first commercial proof-of-concept
- Late 2026 / Q1 2027: MOMENTUM Phase 3 Graves' disease primary endpoint readout — largest single catalyst
💬 Daniel's Take
Immunovant is a classic high-risk, high-reward clinical-stage biotech with a binary catalyst (MOMENTUM Graves' disease Phase 3) and a structural overhang (Roivant 57%). The bull case is clean: IMVT-1402's cleaner albumin profile differentiates from efgartigimod, Graves' disease is a virgin biologic market, and the multi-indication platform provides diversification. The bear case is also clean: Phase 2 Graves' efficacy was modest, argenx Vyvgart is entrenched and Phase 2 Graves' data is approaching, and the Roivant 57% creates structural ambiguity. The 20.9% short interest is the contrarian bull signal but the binary catalyst risk is real. I size IMVT at 0.5-1% as the speculative-biotech option in a diversified portfolio — small enough that a MOMENTUM miss is acceptable, large enough that a clean win generates meaningful portfolio contribution. The trade I would not make is sizing above 1.5% — single-clinical-readout binary risk plus Roivant overhang creates downside scenarios that should not dominate a portfolio. Add trigger: MOMENTUM Phase 3 primary endpoint win combined with no Roivant adverse strategic move. Cut trigger: MOMENTUM miss or any argenx Graves' Phase 2 data showing efficacy parity. This is a binary-catalyst trade with a 60/40 probability skew based on Phase 2 data — sized accordingly.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Immunovant?
Compare top-rated brokers — low fees, trusted providers, fully regulated.